219508-19-7

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-1H-indole-6-carboxylic acid is used as an intermediate in the synthesis of pharmaceuticals for its potential applications in the development of antineoplastic, antimicrobial, and antifungal agents. Its unique structure and functional groups enable the creation of new compounds with diverse biological activities, making it a promising candidate for the advancement of medicinal chemistry.
Used in Organic Synthesis:
In the field of organic synthesis, 3-Bromo-1H-indole-6-carboxylic acid is used as a valuable building block for the creation of new compounds with diverse applications. The presence of the bromine atom allows for further chemical modifications, enhancing its versatility and potential for diversification in various organic synthesis processes.
Used in Antineoplastic Agents Development:
3-Bromo-1H-indole-6-carboxylic acid is used as a key component in the development of antineoplastic agents, contributing to the discovery and synthesis of novel compounds with potential anticancer properties. Its unique structure and functional groups play a crucial role in the design and synthesis of new antineoplastic agents, offering promising therapeutic options for cancer treatment.
Used in Antimicrobial and Antifungal Agents Development:
3-Bromo-1H-indole-6-carboxylic acid is also used in the development of antimicrobial and antifungal agents, leveraging its potential applications in the synthesis of new compounds with broad-spectrum activity against various microorganisms. Its unique structure and functional groups contribute to the discovery of novel agents with improved efficacy and selectivity in combating microbial infections.

InChI:InChI=1/C9H6BrNO2/c10-7-4-11-8-3-5(9(12)13)1-2-6(7)8/h1-4,11H,(H,12,13)

Upstream product

• 860457-92-7 methyl 3-bromo-1H-indazole-6-carboxylate 

Relevant academic research and scientific papers

SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF

Provided is a compound of formula (I)[Formula (I) should be inserted here], in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/ or lactate dehydrogenase B (LDHB) activity in a cell.

Vanilloid receptor ligands and their use in treatments

Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

Antithrombotic agents

This application relates to a compound of formula (I), a pharmaceutically acceptable salt of the compound, or a prodrug thereof, as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.